Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Soltau

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Idrugs : the Investigational Drugs Journal|April 2, 2004
ZD-6126 AstraZenecaJens Soltau, Joachim Drevs
Expert Review of Anticancer Therapy|May 19, 2009
Mode of action and clinical impact of VEGF signaling inhibitorsJens Soltau, Joachim Drevs
Onkologie|March 20, 2009
Molecular targeted therapies for solid tumors: management of side effectsViktor Grünwald, Jens Soltau, Philipp Ivanyi, et al.
Archiv Der Pharmazie|October 8, 2005
Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigenFelix Kratz, Ahmed Mansour, Jens Soltau, et al.
Anticancer Research|May 30, 2008
Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA modelJens Soltau, Ute Zirrgiebel, Norbert Esser, et al.
Oncology Reports|December 4, 2009
Anti-tumor effects of AMT in the renal cell carcinoma modelMarcello Caballero, Jürgen Scheele, Ute Zirrgiebel, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Idrugs : the Investigational Drugs Journal|April 2, 2004
ZD-6126 AstraZenecaJens Soltau, Joachim Drevs
Expert Review of Anticancer Therapy|May 19, 2009
Mode of action and clinical impact of VEGF signaling inhibitorsJens Soltau, Joachim Drevs
Onkologie|March 20, 2009
Molecular targeted therapies for solid tumors: management of side effectsViktor Grünwald, Jens Soltau, Philipp Ivanyi, et al.
Archiv Der Pharmazie|October 8, 2005
Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigenFelix Kratz, Ahmed Mansour, Jens Soltau, et al.
Anticancer Research|May 30, 2008
Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA modelJens Soltau, Ute Zirrgiebel, Norbert Esser, et al.
Oncology Reports|December 4, 2009
Anti-tumor effects of AMT in the renal cell carcinoma modelMarcello Caballero, Jürgen Scheele, Ute Zirrgiebel, et al.
Pageof 1